Document is current
Any future updates will be listed below
-
Authors
Javaheripour, Nooshin
Li, Meng
Chand, Tara
Krug, Axel https://orcid.org/0000-0002-0564-2497
Kircher, Tilo
Dannlowski, Udo
Nenadić, Igor
Hamilton, J. Paul https://orcid.org/0000-0001-7982-4659
Sacchet, Matthew D.
Gotlib, Ian H. https://orcid.org/0000-0002-3622-3199
Walter, Henrik https://orcid.org/0000-0002-9403-6121
Frodl, Thomas https://orcid.org/0000-0002-8113-6959
Grimm, Simone
Harrison, Ben J.
Wolf, Christian Robert
Olbrich, Sebastian
van Wingen, Guido https://orcid.org/0000-0003-3076-5891
Pezawas, Lukas https://orcid.org/0000-0002-1329-6352
Parker, Gordon
Hyett, Matthew P.
Sämann, Philipp G.
Hahn, Tim https://orcid.org/0000-0001-6541-3795
Steinsträter, Olaf
Jansen, Andreas
Yuksel, Dilara
Kämpe, Robin
Davey, Christopher G. https://orcid.org/0000-0003-1431-3852
Meyer, Bernhard
Bartova, Lucie https://orcid.org/0000-0002-1769-8025
Croy, Ilona
Walter, Martin
Wagner, Gerd https://orcid.org/0000-0003-2296-0259
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB779-A06)
- License Information
-
More Information
Article History
Received: 3 August 2021
Revised: 31 August 2021
Accepted: 13 September 2021
First Online: 7 October 2021
Competing interests
: SG has served as consultant to and received research support from Boehringer Ingelheim. MW performed studies with institutional research support from HEEL and from Janssen Pharmaceutical Research for an IIT on ketamine in patients with MDD, which is unrelated to this investigation. MW has not received any personal financial compensation from third parties. All other co-authors declared no conflict of interests.
